Closed-loop micromagnetic neuromodulation as a non-opioid treatment for neuropathic pain. - in this sbir phase i proposal, quantum nanostim will develop a closed loop omnidirectional neuromodulation…

Ended Project Grant Awarded Last action

Award ID
R43NS120335
Recipient
Awarding agency
Obligated
$2,000,000

Award facts

Assistance listing
93.279 Drug Use and Addiction Research Programs
Completion date
Originally
Funding
  • $1,500,000.00 Federal
  • $500,000.00 Non-federal
Place of performance
Nashville, TN 37232, USA

Award details come from USAspending.gov.

Description

Closed-loop micromagnetic neuromodulation as a non-opioid treatment for neuropathic pain. - in this sbir phase i proposal, quantum nanostim will develop a closed loop omnidirectional neuromodulation with electromagnetic fields (clone) system to provide improved pain relief with greater specificity for those suffering from chronic neuropathic pain and opioid dependence. Chronic neck and low back pain accounts for the third highest amount of US health care spending (estimated $88 billion). Spinal cord stimulation (SCS) has provided pain relief for 60% of those with chronic pain and eliminated opioid use entirely in more than 50%. One of the leading barriers to the traditional SCS is encapsulation of the electrodes by glial cells, referred to as glial encapsulation or glial scar (gliosis). Several studies have shown advantages of magnetic-based neuromodulation relative to traditional electrical stimulation, including: (a) the magnetic field is not affected by glial encapsulation, (b) depolarization of the targeted neurons can occur from a greater distance more consistently, (c) magnetic stimulation affords high orientation specificity, and (d) increased battery life due to decreased implantable pulse generator (IPG) energy consumption. Magnetic stimulation can be used in combination with traditional SCS to form new hybrid waveforms. However, there are no current commercial devices that utilize this form of treatment. This modality is needed to advance the field of neuromodulation. The clone array will provide an ultra-thin and conformal blanket of stimulation contacts across the entire width of the dorsal spinal surface. A novel active-lead controller implantable pulse generator (AL-IPG) powers the chip safely, synchronizes with the active-lead electronics, configures the 10 programmable "therapy groups", and ensures therapy pulses are delivered to the tissue. The clone system is a novel solution for the treatment of patients suffering from chronic pain and opioids. In this phase i we will perform key development steps and demonstrate safety and feasibility, positioning US for completion of development and verification and validation during phase II.

Transactions

Action Federal Non-federal Date
Amendment $0 $0
Amendment $0 $0
Amendment $0 $0
Amendment $500,000 $0
Amendment $500,000 $0
Original award $500,000 $500,000

Quick answers

Who received award R43NS120335?

R43NS120335 was awarded to Quantum Nanostim LLC by National Institute of Neurological Disorders and Stroke (National Institutes of Health) on September 1, 2021.

How much is award R43NS120335 worth?

$2,000,000 has been obligated on R43NS120335: $1,500,000 in federal funding and $500,000 in non-federal funding.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award